News

DBV Technologies Unveils New ATM Program for Investor Funding

DBV Technologies Unveils New ATM Program for Investor Funding

DBV Technologies Launches At-The-Market Program

DBV Technologies (NASDAQ: DBVT) has recently put into motion an At-The-Market (ATM) offering program, aiming to enhance its financial flexibility. The company, known for its innovative biopharmaceutical solutions for food allergies, aims to raise a total gross amount of up to $150 million through this initiative. The announcement follows the filing of a prospectus supplement with the U.S. Securities and Exchange Commission (SEC).

What is the ATM Program?

The ATM Program allows DBV Technologies to sell its American Depositary Shares (ADS), where each ADS corresponds to five ordinary shares. This program is designed to facilitate sales directly in the market, capitalizing on interest from various investors. Under this program, sales will be conducted as market conditions allow, enabling DBV Technologies to respond dynamically to investor demand.

Sales Process and Structures

Through a sales agreement with Citizens JMP Securities, acting as sales agent, DBV Technologies is prepared to offer these ADSs to eligible investors. The sales strategy will align with typical market practices, ensuring effective price setting based on current market value. This strategic adaptation is meant to optimize proceeds while adhering to established regulatory limits.

Intended Use of Proceeds

The funds raised through the ATM Program are targeted for several pivotal uses. Primarily, they will support the activities surrounding the Biologics License Application (BLA) for VIASKIN® Peanut—a treatment designed for toddlers aged 1-3 suffering from peanut allergies. Additionally, the proceeds will help advance the development of other potential product candidates using DBV's proprietary technology.

A Focus on Innovative Treatment Options

DBV Technologies is dedicated to providing solutions in the realm of food allergies, relying on its epicutaneous immunotherapy (EPIT) approach. This cutting-edge treatment method is aimed at gradually desensitizing individuals to allergens through the application of its VIASKIN® patch. This non-invasive approach seeks to address a significant health issue faced by millions globally.

Current Projects in Development

The company is engaged in several clinical trials, particularly focusing on the VIASKIN® Peanut patch. This treatment is crafted to cater specifically to young children who are at risk of severe allergic reactions. The company aims to modify the immune system’s response to allergens, ultimately improving patient outcomes and quality of life.

Market Impact and Future Strategies

As the ATM Program progresses, DBV Technologies plans to provide regular updates on its capital utilization and developments related to the sale of ADSs. This transparency is crucial for maintaining investor trust and engagement, illustrating DBV's commitment to growth and innovation.

Investment Opportunities

Prospective investors are encouraged to consider DBV’s strategic advancements as they reflect on investment opportunities within the biopharmaceutical sector. The ATM Program provides a novel way for investors to engage with a company that is at the forefront of addressing urgent healthcare challenges, particularly in food allergy treatments.

Frequently Asked Questions

What is the purpose of DBV Technologies' ATM program?

The ATM program is designed to raise funds for bolstering the company's initiatives, particularly for the BLA of the VIASKIN® Peanut patch targeting food allergies.

How does DBV's ATM program work?

The program allows the company to sell ADSs directly in the market as conditions allow, based on investor interest and market prices.

What are the expected uses of the funds raised?

Funds will primarily support the BLA process for the VIASKIN® Peanut patch and further development of the company’s product candidates.

Who can participate in the ATM program?

Eligible institutional and qualified investors as per the terms outlined in the sales agreement can purchase ADSs under the ATM program.

Why is DBV Technologies focusing on food allergies?

Food allergies represent a significant health challenge, especially among young children, and DBV Technologies is committed to developing innovative treatments to address this urgent need.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 0

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 26

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 467

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 48

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 51

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 244

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

EDF Renewables Partners with OPPD for Sustainable Energy Growth

Updated Category News Views 184

EDF Renewables and Omaha Public Power District Join Forces EDF Renewables North America has announced a significant partnership with Omaha Public Power District (OPPD) to enhance the future of renewable energy. Their collaboration centers around the Milligan 1 Wind project, contributing to a larger initiative aimed at delivering cleaner, reliable energy to communities...

Continue Reading
Seaport Therapeutics Welcomes Lauren White as CFO in Growth Strategy

Updated Category News Views 128

Seaport Therapeutics Appoints Lauren White as Chief Financial Officer Seaport Therapeutics, a pioneering clinical-stage biopharmaceutical firm focused on developing innovative neuropsychiatric therapies, recently announced an important leadership change, naming Lauren White as their new Chief Financial Officer. With an impressive track record in biotech financial...

Continue Reading
Lyte Fiber Secures $58 Million to Enhance Broadband Access

Updated Category News Views 461

Lyte Fiber Secures Funding to Expand Broadband Connectivity Lyte Fiber, LLC, based in Houston, has been awarded nearly $58 million through the State’s Bringing Online Opportunities to Texas (BOOT) II Program. This significant funding initiative aims to connect more than 6,750 underserved homes and businesses, thereby supporting the goal of widening broadband access in...

Continue Reading
Chipotle Faces Challenges as Young Consumers Turn to Home Cooking

Updated Category News Views 233

Understanding Current Dining Trends and Chipotle's Position As inflation continues to affect the retail and restaurant sectors, many dining establishments are feeling the pinch, particularly as lower-income consumers scale back on discretionary spending. Chipotle Mexican Grill Inc. (NYSE: CMG) recently faced significant losses in its stock value, dropping 19% in a single...

Continue Reading
Leadership Changes Propel zerohash for Future Growth

Updated Category News Views 288

Leadership Appointments at Zerohash New York-based zerohash has made significant strides in the crypto and stablecoin sector by welcoming Aaron Karczmer and Danny Rosenthal to its Boards of Directors. Their wealth of experience in payments and regulatory frameworks will be instrumental as the company navigates its next growth phase. Bringing Expertise to the Board Aaron...

Continue Reading